All In Biotech

Drug Trial Radar · NCT00113607

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 672 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

672

Actual

Start

Apr 2005

Primary completion

Nov 2010

Study completion Nov 2010

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
PharmaMar
First posted
Jun 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • TrabectedinDrug

    Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.

  • DOXILDrug

    Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.

  • DexamethasoneDrug

    Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS): Independent Radiologist ReviewTime frame: From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years

Locations

111 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Newport Beach, California

  • Site not named

    Orange, California

  • Site not named

    Englewood, Colorado

  • Site not named

    Stamford, Connecticut

  • Site not named

    Tampa, Florida

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Morristown, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Greenville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Chattanooga, Tennessee

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Galveston, Texas

  • Site not named

    Buenos Aires, Argentina

  • Site not named

    Mendoza, Argentina

  • Site not named

    Sante Fe, Argentina

  • Site not named

    Adelaide, Australia

  • Site not named

    Bentleigh, Australia

  • Site not named

    Douglas, Australia

  • Site not named

    St Leonards, Australia

  • Site not named

    Toorak Gardens, Australia

  • Site not named

    Edegem, Belgium

  • Site not named

    Hasselt, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Wilrijk, Belgium

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.